Peak Bio appoints Sandip Patel as director and Audit Committee chair

Peak Bio, Inc.

Sandip Patel appointed as Class III director and Audit Committee chair effective August 8, 2024.
Patel participated in May and July 2024 financings totaling $275,500.
He brings experience in biotech M&A and finance; previously served as General Counsel at WellCare.
No family relationships or arrangements with other directors or officers.
Board cites his advisory background in biopharma for appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandip Patel

Class III Director and Audit Committee Chair

Peak Bio, Inc.

Effective: 2024-08-08
Filed: August 14, 2024, 7:59 PM ET

On August 8, 2024, the Board of Directors of Peak Bio, Inc. (the “Company”) appointed Sandip Patel as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandip Patel was appointed as Class III Director and Audit Committee Chair at Peak Bio, Inc..

Action: appointed
Role: Class III Director and Audit Committee Chair

Exact text from the filing

On August 8, 2024, the Board of Directors of Peak Bio, Inc. (the “Company”) appointed Sandip Patel as a director of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-097086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.